Prior to FDA approval of intradetrusor botulinum toxin (BoTA) injections for the treatment of neurogenic bladder, patients' treatment options were limited to use of pharmacotherapies such as antimuscarinics, alpha blockers, and more recently beta agonists (some offlabel) or invasive interventions including bladder augmentation and urinary diversion procedures. Herein, we provide a comprehensive literature review detailing the salient clinical literature that led to FDA approval of intradetrusor BoTA for neurogenic bladder. Patients with neurogenic detrusor overactivity and detrusor sphincter dyssynergia have been shown in randomized studies to benefit significantly from intradetrusor BoTA injection with regard to the following parameters: improved voided volume, improved bladder pressure and urodynamic parameters, reduced incidence of urinary tract infection, and improved quality of life. Intradetrusor BoTA injection has revolutionized the treatment landscape for patients with neurogenic bladder by providing them with a safe, efficacious, and cost-effective means to reduce bladder dysfunction, preserve renal function, and reduce the need for invasive, surgical intervention.
Introduction

Physiology of Normal Bladder Function
Neuronal control of micturition involves a complex, coordinated circuit linking the cerebral cortex to the bladder and bladder outlet (bladder neck, urethra, urethral sphincter) to allow for safe bladder filling, storage, and emptying [1, 2] . As a general overview, micturition is divided into a filling phase and voiding phase [1, 2] . Filling requires a compliant bladder and a competent outlet. During filling, sympathetic efferents from T11 to L2 carried by the hypogastric nerve promotes detrusor relaxation and increased sphincter tone and permits urine to collect in a low-pressure reservoir to avoid reflux of urine to the kidney [1, 2] . During voiding, the pontine micturition center (Barrington nucleus) inhibits sympathetic and stimulates parasympathetic input to the bladder and urethral sphincter. Parasympathetic innervation from sacral S2-S4 nerve roots promotes detrusor contraction, which is immediately preceded by external sphincter relaxation. The external sphincter is composed of skeletal muscle innervated by somatic nerves, which when relaxed in conjunction with detrusor contraction allows for bladder emptying. The coordinated events of filling and voiding may be disrupted in neurologic disease as a result of aberrant afferent and efferent signaling to the bladder and outlet [1] [2] [3] .
Neurogenic Bladder: Neurogenic Detrusor Overactivity and Detrusor Sphincter Dyssynergia
Neurogenic bladder refers to bladder dysfunction secondary to neurologic disease affecting any point in the complex, neuronal circuit described above, which can ultimately compromise safe filling and emptying. Given the wide range of neurologic conditions that cause neurogenic bladder, it is not surprising that the resulting degree and characteristics of bladder dysfunction can be quite variable among patients. As a general rule, the location of the lesion (suprapontine, suprasacral spinal cord, sacral spinal cord, or peripheral nerve) can help to predict the type of lower urinary tract dysfunction that may arise, but patient symptoms can be highly variable even among those with a similar diagnosis and lesion location (Table 1) [3] . For the purposes of this article, we focus on the treatment of upper motor neuron lesions causing bladder dysfunction, specifically lesions to the cerebral cortex and suprasacral spinal cord ( Table 1) .
The degree and type of bladder and sphincter dysfunction is diagnosed using urodynamics testing and should be repeated periodically to assess changes in bladder function as neurologic disease progresses and response to treatment [4] . Urodynamics utilizes cystometry, electromyography, uroflowmetry, and pressure-flow studies to evaluate key parameters of filling and voiding, including bladder sensation, detrusor compliance, sphincter function, presence of uninhibited detrusor contractions, detrusor/sphincter synergy during voiding, detrusor leak point pressure, bladder capacity, and postvoid residual (PVR) volume [4] .
Neurogenic detrusor overactivity (NDO) most often occurs with suprapontine and cerebral cortex insults, including stroke, multiple sclerosis (MS), and Parkinson disease but can also occur with suprasacral spinal cord injury (SCI) [5] (Table 1) . Symptoms include urinary urgency, frequency, nocturia, and incontinence, which negatively impact quality of life in many patients [5, 6] . Diagnostic findings on urodynamics include impaired detrusor compliance, high detrusor leak point pressure, high amplitude detrusor contractions, uninhibited detrusor contractions, and high PVR volume [4, 7] .
Detrusor sphincter dyssynergia (DSD) most often occurs in patients with suprasacral SCIs or lesions (eg, MS) (Table 1 ). Similar to NDO, patients often experience urinary urgency, frequency, nocturia, and incontinence as well as urinary retention and obstructive voiding symptoms [8] . DSD is a urodynamic diagnosis typically defined as sphincter contraction, or inability to relax, during detrusor contraction [8] .
Treatment Strategies Before Availability of Botulinum Toxin A (BoTA) Classically, treatment strategies have aimed at symptomatic relief as well as reduction in clinical sequelae including urinary tract infection (UTI) and renal deterioration from elevated bladder pressures and urine reflux [4, 5] . Prior to U.S. Food and Drug Administration (FDA) approval of intradetrusor BoTA injections for the treatment of NDO and DSD described below, treatment options included pharmacotherapies (antimuscarinics [AMs], alpha-blockers), assisted bladder drainage (intermittent catheterization, suprapubic catheterization, chronic indwelling Foley catheter), neuromodulation, surgical intervention such as sphincterotomy, urinary diversion or bladder augmentation, or a combination approach.
Antimuscarinics
Following bladder denervation, such as in SCI, significant bladder remodeling occurs that includes an increase in detrusor muscarinic receptor density and sensitivity [9] . They may develop high-pressure contractions during filling (termed uninhibited detrusor contractions), which may or may not result in incontinence and/or autonomic dysreflexia, and low capacity, or a lack of appropriate relaxation during filling resulting in impaired compliance. AMs are the most commonly used and cited therapy for neurogenic bladder and is considered a first-line therapy [9] . The goal of AMs is to manage incontinence, potentially restore continence, and ultimately protect upper tract function [9, 10] . In a comprehensive review of oral AMs in neurogenic bladder by Madersbacher et al, both randomized control studies and small, open label trials have shown AMs to decrease maximum detrusor pressure, improve bladder capacity, and improve quality of life [10] . The most studied are oxybutynin and trospium, both of which show dose-dependent improvements in efficacy [10] [11] [12] . The drawback to many studies included, however, is short duration, and therefore long-term sequelae, such as upper tract dysfunction over time cannot be assessed [10] [11] [12] . Oral AMs are typically well tolerated but up to 61% of patients report adverse effects including dry mouth, constipation, urinary retention, dizziness, and blurred vision [9] [10] [11] [12] [13] . Furthermore, increasing doses of AMs are often utilized over time with worsened side effects, which ultimately affects compliance [13] .
Intravesical AMs, most commonly oxybutynin, is also an option in which pills are crushed, diluted in water or saline, and then instilled into the bladder via a catheter [9] [10] [11] [12] [13] . Prospective studies in both children and adults have shown that this application is well tolerated, with significantly reduced side effects compared to oral therapy, and is efficacious, with significant improvements in maximum detrusor pressure, bladder capacity, and even continence [9, [13] [14] [15] .
Lastly, it is important to note that the use of AM agents, whether oral or intravesical, often require concomitant intermittent catheterization or other method of assisted bladder drainage.
Alpha-blockers
Many patients with neurogenic bladder are unable to void on their own, but those who are have been shown in some studies to have symptomatic and urodynamic improvements with alpha-blockers such as tamsulosin with bladder emptying. In a 1-year open label trial of 186 patients comparing placebo to tamsulosin in patients with MS, those taking tamsulosin had significant improvements in PVR, voiding time, bladder capacity, and maximal urethral pressure [16] . A similar open label study in 263 patients with suprasacral SCI, however, did not show significant differences [17] . Although further research is needed to better understand the mechanism and efficacy of alpha-blockers in neurogenic bladder patients, it does remain a viable pharmacotherapy to consider in patients who void volitionally.
Assisted Bladder Drainage (Intermittent Catheterization, Suprapubic Catheterization, Chronic Indwelling Foley Catheter)
Given the majority of neurogenic bladder patients do not void volitionally, many require assistance with bladder drainage using either clean intermittent catheterization (CIC) or an indwelling catheter (IC). An efficient bladder management strategy avoids overfilling, reflux of urine to the kidneys, and ultimately renal scarring and deterioration. CIC is generally the preferred method of catheterization as it improves self-care, reduces risk of UTI over IC, and reduces barriers to sexual function [18] . An indwelling urethral catheter is often used when patients fail or unable to perform CIC; however, it increases risk of UTI, bladder stone formation, renal impairment, urethral stricture, urethral erosion, and bladder cancer [18] . Studies have shown that up to 90% of patients prefer suprapubic catheterization over a urethral IC [19] . Suprapubic catheterization can improve hygiene, ease of catheter changes, and risk of iatrogenic epididymitis and hypospadias; however, it does not change other risks, including symptomatic infections and elevated risk of bladder cancer [20] .
Sacral Neuromodulation
Sacral neuromodulation is a staged procedure during which a quadripolar lead is placed percutaneously into the S3 foramen under fluoroscopic guidance and attached to an external pulse generator. If patients experience a greater than 50% improvement in urinary symptoms, an implantable pulse generator is then placed [21] . This intervention is not currently FDA approved for patients with neurogenic bladder but is often used off-label. In patients with neurogenic bladder, success rates have been quoted as 50% to 68% during the initial test phase and 70% to 92% after the implantation phase, which is comparable to nonneurogenic patients' [21, 22] . In patients with MS, several small studies have shown reduced urinary frequency by up to 9 voids per day, increased voided volume, and reduced episodes of incontinence [23, 24] . However, these studies do not account for baseline severity of neurologic disease and do acknowledge failure rates from 16% to 33% by 4 years [23, 24] . In a pooled meta-analysis of all-comers with neurogenic bladder, patients had a pooled success rate of >75% at 28 days after final implantation [25] . In this study, success was defined as >50% in bladder diary variables (number of leakages, pad use, number of voids, number of catheterizations). With regard to safety, in this pooled meta-analysis of 224 patients from 22 studies, 69 patients required reoperation after permanent implantation [25] . Most common side effects reported are lead migration, pain at site of implant, infection at lead site, and lead fracture [21, 25] . Lastly, neuromodulation may have other benefits, including improved bowel and erectile function. In one small study of 6 patients with SCI, all 6 patients had improvement in SHIM scores (Sexual Health Inventory in Men) and were able to stop oral erectile medication, and 2 of 6 had >50% improvement in bowel symptoms [26] .
Surgical Interventions
Surgical procedures used in this population are typically to either enhance sphincteric continence (urethral bulking agents, pubovaginal and bladder neck slings, artificial urinary sphincters, bulbar urethral slings, and bladder neck closure), to reduce bladder pressures and improve capacity (augmentation cystoplasty), or for ultimate urinary diversion such as ileal conduit [27] . Catheterizable channels to the abdominal wall can also be created, including Mitrofannof (using the appendix) or Monti (using a reconfigured ileum) to allow for catheterization via the abdominal wall, even in patients with cervical-level SCI. Surgical intervention, especially invasive surgeries such as augmentation cystoplasty or urinary diversion procedures, is employed after pharmacotherapies and minimally invasive approaches have failed. These are major abdominal procedures requiring at least a 5-to 7-day hospitalization and are not without risk, including bowel leak, urine leak, deep venous thrombosis, pneumonia, and even mortality. As we discuss below, the importance of new innovative therapies such as intravesical BoTA is that it may ultimately decrease the number of patients progressing toward requiring these invasive therapies.
Long-term, postoperative complications after augmentation cystoplasty include perforation, metabolic derangements, stone formation, renal deterioration, incontinence and malignancy [28] . With regard to bladder stone formation, this population is at increased risk given urine stasis, mucus production, increased risk of UTI with urease positive organisms, and catheterizing through an abdominal channel [29, 30] . Incidence ranges from 11% to 36% and prevention strategies are of upmost importance including mucus irrigation, strict adherence to catheterization regimens, and treatment of UTI and chronic infections [28] . With regard to malignancy, while the exact incidence is unknown and likely underreported, it is known that patients with neurogenic bladder have a higher rate of bladder cancer, are diagnosed at a younger age, and commonly have more advanced staged cancer at presentation compared to the general population [31] . Although the exact mechanism is unknown, it is thought to relate to chronic inflammation. There are currently no consensus guidelines for long-term bladder cancer screening in this population, but the literature suggests starting surveillance cystoscopy 10 years after augmentation [32] .
Literature Search Strategy
Existing literature was searched systematically to identify articles relating to neurogenic bladder, neurogenic detrusor overactivity, detrusor sphincter dyssynergia, botulinum toxin, and more specifically intravesical botulinum toxin. The search was conducted in December 2017 across 4 bibliographic sources: PubMed, Cochrane Central, EMBASE, and Scopus. Search terms were developed using combinations of the following key words: neurogenic bladder, neurogenic detrusor overactivity, detrusor sphincter dyssynergia, botulinum toxin type A, intravesical, bladder, spinal cord injury, multiple sclerosis, side effect, pain, post void, urinary retention, urinary tract infection, infection, vesicular-ureteral reflux, reflux, catheter, catheter-dependent, clean intermittent catheterization, autonomic dysreflexia, outcome, patient satisfaction, safety, cost, injection template, administration, trigone, trigone-sparing, dome, domesparing, flexible cystoscopy. An author search was conducted using Scopus to identify similar and related articles published by a single author regarding related topics.
Botulinum Toxin in the Treatment of NDO and DSD
Botulinum Toxin: Mechanism of Action, Types, and FDA Status Botulinum toxin is a neurotoxin produced by Clostridium botulinum, which inhibits calcium-mediated release of acetylcholine (Ach) from presynaptic, cholinergic nerve terminals resulting in neuromuscular blockade [33, 34] . This blockade leads to temporary loss or reduction in muscle contraction and muscle atrophy at affected sites [25, 26] . Furthermore, BoTA exerts inhibitory effects on stimulatory neurotransmitters, neuropeptides, and their receptors, which affect sensory nerve fibers and improves the sensation of urgency [35] .
Although 7 antigenic subtypes of botulinum toxin exist (A, B, C, D, E, F, and G) , only A and B are commercially available and approved by the FDA (August 24, 2011) for therapeutic use [36] [37] [38] . Specifically, they can be injected into the detrusor muscle, external urethral sphincter, or both depending on the indication. Of the two, botulinum type A (BoTA) is most commonly used given its increased potency and longer duration of action [36, 37] . Dykstra et al described the first use of BoTA for a urologic indication in 1988 in a small study of SCI patients with detrusor sphincter dyssynergia (DSD), which noted improvement in PVR and urethral pressure following external urethra sphincter injection of BoTA [39] . Since this study, others have sought to describe the potential benefits of BoTA for other indications, including benign prostatic hyperplasia, nonneurogenic overactive bladder, chronic pelvic pain, and NDO [33, 38] .
Method of Administration and Injection Template
For detrusor injection, BoTA is administered as a series of intradetrusor injections throughout the bladder using rigid or flexible cystoscopy under local, regional, or general anesthesia [40, 41] . One advantage of flexible cystoscopy is that it avoids positioning in lithotomy, which can be difficult in this population because of joint contractures. Dosing is based on 2 pivotal randomized studies that demonstrated optimal dosing at 200 to 300 U with no increased benefit at >300 U with regard to incontinence or quality of life [42, 43] . Although many injection templates have been proposed, there is currently no strict consensus. The majority include injections to the lateral walls and base, with or without trigone of the bladder [5, 40, 41] . Some propose to avoid dome injections to prevent possible intraperitoneal injection of BoTA [40] .
The FDA and manufacturer insert recommend a trigone-sparing template, which mirrors the template used in the 2 pivotal trials by Ginsberg et al and Cruz et al discussed below that ultimately led to FDA approval of intravesical BoTA [38, 42, 43] . This recommendation is controversial and based on the theoretical risk of vesicular-ureteral reflux with trigone injection. However, several studies including a meta-analysis have failed to demonstrate increased risk of vesicular-ureteral reflux or differences in treatment efficacy when comparing trigone to trigone-sparing injection templates [44] [45] [46] . In fact, 2 randomized controlled trials in SCI patients showed that including trigone injections enhanced efficacy [47, 48] . It is unclear in the literature how practicing urologists have modified their individual injection templates based on FDA recommendation vs these studies, which propose that trigone injections may enhance their patient outcomes. The authors of this review use the template depicted in Figure 1 . When performing BoTA injection with flexible cystoscopy, it is very difficult to inject the trigone given the angle of the scope. However, when using rigid cystoscopy, the author will perform one injection to the center of the trigone (Figure 1) .
Outcomes of Intravesical BoTA in NDO and DSD
The data supporting the use of BoTA in patients with NDO comes from 2 double-blind, randomized, placebo- (Table 2) [5, 42, 43] .
Cruz et al recruited 153 patients with MS and 117 patients with SCI who had urinary incontinence (UI) due to NDO defined as ≥14 episodes UI/week [42] . At the time of study entry, 21.4% of MS and 91.6% of SCI patients performed CIC. Patients must have failed prior anticholinergic therapy for at least 1 month, but were permitted to continue this medication during the trial. Patients were randomized to a one-time treatment of 30 × 1-mL intradetrusor BoTA (200 U or 300 U) or placebo injections and subsequently followed for 52 weeks with visits at 2, 6, and 12 weeks then every 6 weeks thereafter. 39 .6% (300 U) of patients became completely dry at 6 weeks posttreatment compared to 7.6% (placebo). Quality of life and urodynamic parameters (detrusor compliance, bladder capacity, and maximum detrusor pressures with voiding) significantly improved in both MS and SCI patients. Overall, clinical efficacy did not vary between 200 and 300 U of BoTA. Side effects associated with BoTA use were dose dependent. With 200 U BoTA, complications included UTI in 56% and urinary retention in 19.8%, which was more common in MS patients who did not perform CIC prior to treatment [42] .
Ginsberg et al recruited 227 patients with MS and 189 with SCI using identical study guidelines to assess the same outcomes set for by Cruz et al. This multicenter, randomized, placebo-controlled trial too noted significant reduction in UI episodes/week, improved quality of life, and improved urodynamics parameters with BoTA compared to placebo (Table 2) . Similarly, dose of BoTA (200 or 300 U) did not matter with respect to treatment efficacy, and duration of effect with both doses was 37 weeks. Furthermore, adverse side effects of treatment occurred at similar rates and included UTI and urinary retention [43] .
Following these 2 pivotal trials, Kennelly et al conducted a 3-year prospective study in 396 patients with SCI and MS to assess the long-term efficacy of BoTA injections. Patients were eligible for repeat BoTA injection after 12 weeks from prior injection. With 200-U injections, median efficacy was 9 months, which included improvements in UI/week, quality of life, and urodynamic parameters [49] . Interestingly, although patients continued to experience benefits in UI episodes, overall dryness, quality of life, and mean voided volume after 5 consecutive treatments, complications of UTI and urinary retention decreased with each subsequent treatment (Table 3) . Overall, Cruz, Ginsberg, and Kennelly BoTA = botulinum toxin A; NDO = neurogenic detrusor overactivity; UI = urinary incontinence episodes per week; n = number of patients; % Dry = percentage of patients stating they are 100% dry at 6 weeks; QOL = quality of life; MCC = maximum cystometric capacity; UR = percentage with urinary retention; UTI = percentage with urinary tract infection; RCT = randomized controlled trial.
et al provide quality evidence to support the FDA's approval of BoTA for NDO and align with the current treatment dosing recommendations of 200-U BoTA in patients with NDO [42, 43, 49] .
Use of BoTA in DSD
DSD is characterized by uncoordinated, simultaneous contractions of the detrusor and external sphincter, which leads to high detrusor pressure, elevated PVRs, and in some patients autonomic dysreflexia. BoTA is typically used as an injection to the external sphincter to cause relaxation and permit emptying. Unfortunately, data guiding the use of BoTA for the treatment of DSD is not as strong and consistent as seen with NDO and consists mostly of low-powered studies. One multicenter, doubleblind, randomized trial of 86 patients with MS-associated DSD found that 100 units of BoTA injection into the urethral sphincter compared to placebo caused no statistical change in PVR between groups but did significantly improve voided volume and detrusor pressure during voiding [50] . Several other small studies, however, did note improvement of PVR with BoTA injection into the urethral sphincter, but these studies were performed in SCI, not MS, patients [51] [52] [53] . Although these studies are low-powered, a recent meta-analysis of BoTA use in SCI patients with DSD did point to the potential efficacy of BoTA with an average PVR decrease from 251.8 mL to 153.0 mL up to 6 months postinjection as well as a reduction in sequelae of UTI and need for CIC in some studies [54] . Overall, the evidence supporting the use of BoTA in DSD is not as definitive as that available for NDO, but still does suggest BoTA is a reasonable treatment option for patients with DSD, especially those with SCI. Additional research is needed, however, to further define this treatment strategy in neurogenic bladder patients with DSD.
Safety and Side Effects
Intravesical BoTA is a safe and generally well-tolerated procedure. It can be performed under local, regional, or general anesthesia. The authors perform more than 90% of such injections in the office with local anesthesia. Most commonly, instillation of intravesical 2% lidocaine prior to the procedure has been reported to provide sufficient bladder anesthesia [55] .
The most common procedural side effects are UTI and hematuria (typically self-limited), and in patients that void, incomplete bladder emptying and urinary retention. Systemic symptoms following this procedure are extremely rare given the very low dose used and the low affinity of BoTA for peripheral nerves [40] . However, systemic toxicity has been reported in rare instances of severe neurologic disease and with utilization of high doses. Symptoms include generalized muscle weakness, diplopia, blurred vision, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence, and breathing difficulties [56] . Furthermore, patients with neurogenic bladder are unique in their risk for autonomic dysreflexia. Therefore, the procedure should be performed in the presence of trained staff with close blood pressure monitoring [40] . Typical signs include sympathetic surge: hypertension, flushing, pounding headache, anxiety, and nasal congestion. Treatment includes aborting the procedure (removing the stimulus), close hemodynamic monitoring, and antihypertensive therapy including nitro paste. It is good practice to ask patients about prior episodes of autonomic dysreflexia prior to the procedure. A thorough discussion of autonomic dysreflexia pathophysiology and treatment is available by Middleton et al [57] .
Cost Analysis
The cost of incontinence and intermittent catheterization is a significant economic burden on U.S. health care and is particularly burdensome to patients with neurogenic bladder. What makes BoTA revolutionary for patients with neurogenic bladder is studies have shown it can make 40% of patients dry and significantly reduce the need for intermittent catheterization and incontinence in others (Tables 2 and 3) . Although no treatment is without its cost, BoTA can significantly reduce the cost associated with incontinence and need for catheterization (Table 4 ). According to our cost analysis, the yearly cost of BoTA (received every 6 months) is estimated at $2822.84 (Table 4) . With this investment, 40% of patients can achieve dryness and thus save $2121.60/ year in incontinence supplies and may reduce the need or frequency of intermittent catheterization, which if BoTA = botulinum toxin A; NDO = neurogenic detrusor overactivity; Cycle = number of repeat treatments; n = number of patients; UI = urinary incontinence episodes per week; % Dry = percentage of patients stating they are 100% dry at 6 weeks; QOL = quality of life; MV/V = mean volume per void; UR = percentage with urinary retention; UTI = percentage with urinary tract infection.
performed sterilely can be over $8000/year [42, 43] . Furthermore, BoTA has the ability to decrease or take away the need for anticholinergic medication, such as oxybutynin. Oxybutynin is typically taken 2 to 3 times daily, making compliance challenging, and costs patients on average $806.47 per year. Therefore, from an economic perspective, BoTA can reduce the economic burden of incontinence, catheterization, and prescription costs on patients with neurogenic bladder.
Conclusions and Opportunities for Future Research
Neurogenic bladder refers to bladder filling and voiding dysfunction, which arises as a result of neurologic disease or injury. Herein, we focus on suprasacral injury leading most frequently to NDO and DSD, although its efficacy in managing other causes of neurogenic lower urinary tract dysfunction is well documented. Historically, treatment options for these patients have been limited and often must progress to invasive interventions including bladder augmentation or diversion surgeries to avoid sequelae of UTI and renal deterioration from high bladder pressures. Intravesical BoTA has significantly changed the treatment landscape of neurogenic bladder patients as it is a 2-to 3-times-yearly intervention that reduces the economic and physical burdens of incontinence and frequency of catheterization. Furthermore, it has been shown in randomized trials to be very efficacious at promoting continence, improving quality of life, and improving bladder mechanics (urodynamic parameters). Because intravesical BoTA has only been FDA approved since 2011, there is still much research to be done on long-term treatment efficacy, utilization patterns, and differences among urologists, for instance, in prescribing patterns and injection templates. 
